[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 43 of about 43
1. Kao CH, Tsai SC, Wang JJ, Ho YJ, Ho ST, Changlai SP: Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int J Cancer; 2001 Jul 20;95(4):228-31
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report.
  • The purpose of this study was to predict chemotherapy response using technetium-99m methoxyisobutylisonitrile (Tc-MIBI) scintigraphy in untreated adult malignant lymphomas (ML) and compare the response with other prognosis factors.
  • Before chemotherapy, 25 adult patients with ML were enrolled in this study.
  • Chemotherapy response was evaluated in the first 1 to 2 years after completion of treatment by clinical and radiological methods.
  • In our preliminary study, when compared with other prognosis factors, Tc-MIBI scintigraphy was the best tool to predict chemotherapy response in adult patients with ML.
  • [MeSH-major] Drug Resistance, Neoplasm. Lymphoma / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11400115.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


2. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer; 2004 Mar 15;100(6):1179-85
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
  • BACKGROUND: Hyperglycemia, which is not uncommon during the treatment of acute lymphocytic leukemia (ALL), has been shown to be an independent predictor of adverse outcomes among hospitalized patients with undiagnosed diabetes; it also may have the potential to affect leukemic cell proliferation through altered metabolism.
  • The purpose of the current study was to determine the prevalence of hyperglycemia during induction chemotherapy for ALL using a regimen comprised of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) and to determine its effect on survival, duration of disease remission, and treatment-related complications.
  • METHODS: Two hundred seventy-eight adult patients with previously untreated ALL who achieved a complete remission with the hyper-CVAD regimen were evaluated.
  • Hyperglycemia was defined as > or = 2 glucose determinations of > or = 200 mg/dL during the first 30 days of induction chemotherapy.
  • Induction chemotherapy was comprised of fractionated cyclophosphamide at a dose of 300 mg/m2 twice daily on Days 1-3, doxorubicin at a dose of 50 mg/m2 on Day 4, vincristine at a dose of 2 mg on Days 4 and 11, and dexamethasone at a dose of 40 mg on Days 1-4 and Days 11-14 (hyper-CVAD).
  • The complete remission duration (CRD), survival, and treatment-related complications were determined for patients with and without hyperglycemia; differences between the two groups were assessed using standard statistical methods.
  • CONCLUSIONS: Patients with hyperglycemia during induction chemotherapy for ALL with the hyper-CVAD regimen were found to have a shorter CRD, experience a significant increase in overall mortality, and be at an increased risk for developing complicated infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Hyperglycemia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine / adverse effects. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Female. Humans. Infection / etiology. Male. Methotrexate / adverse effects. Methotrexate / therapeutic use. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • [CommentIn] Cancer. 2004 Sep 1;101(5):1100-1; author reply 1101 [15329922.001]
  • (PMID = 15022284.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  •  go-up   go-down


3. Smallegange C, Hale TM, Bushfield TL, Adams MA: Persistent lowering of pressure by transplanting kidneys from adult spontaneously hypertensive rats treated with brief antihypertensive therapy. Hypertension; 2004 Jul;44(1):89-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent lowering of pressure by transplanting kidneys from adult spontaneously hypertensive rats treated with brief antihypertensive therapy.
  • We have hypothesized that pharmacotherapy modifies specific properties of the kidney, particularly the vasculature, such that after kidney transplantation, there are persistent changes in the level of arterial pressure.
  • Consistent with previous studies, a 2-week aggressive treatment of adult (15 weeks) spontaneously hypertensive rats with an angiotensin-converting enzyme inhibitor (enalapril) combined with a low-salt diet induced a persistent change in the kidney and a decrease in arterial pressure (18%).
  • These persistent changes in arterial pressure could be completely transferred to untreated adult spontaneously hypertensive rats by kidney transplantation (ie, pressure in untreated rats was decreased after transplantation of a kidney donated from a previously treated rat).
  • Further, the importance of kidney-specific changes was demonstrated by finding that the treatment-induced lowering of arterial pressure was completely reversed by transferring an untreated kidney into a previously treated rat.
  • The specific treatment-induced changes to the kidney included a decrease in structurally based renal vascular resistance that was similar to the persistent lowering of arterial pressure.
  • These data provide evidence for a link between the treatment-induced changes in kidney vascular structure and the persistent lowering of arterial pressure.
  • The findings also suggest that a key pharmacotherapeutic target in hypertension should be kidney-specific changes, such as renal vascular structure.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Blood Pressure / physiology. Hypertension / therapy. Kidney / blood supply. Kidney Transplantation
  • [MeSH-minor] Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Animals. Diet, Sodium-Restricted. Male. Rats. Rats, Inbred SHR. Vascular Resistance

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15148290.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antihypertensive Agents
  •  go-up   go-down


Advertisement
4. Ryall JG, Plant DR, Gregorevic P, Sillence MN, Lynch GS: Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol; 2004 Feb 15;555(Pt 1):175-88
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted an extensive dose-response study to determine the most efficacious dose of fenoterol for increasing skeletal muscle mass in adult rats and used this dose in testing the hypothesis that fenoterol may have therapeutic potential for ameliorating age-related muscle wasting and weakness.
  • We used adult (16-month-old) rats that had completed their growth and development, and old (28-month-old) rats that exhibited characteristic muscle wasting and weakness, and treated them daily with either fenoterol (1.4 mg kg(-1), i.p), or saline vehicle, for 4 weeks.
  • Following treatment, functional characteristics of fast-twitch extensor digitorum longus (EDL) and predominantly slow-twitch soleus muscles of the hindlimb were assessed in vitro.
  • Untreated old rats exhibited a loss of skeletal muscle mass and a decrease in force-producing capacity, in both fast and slow muscles, compared with adult rats (P < 0.05).
  • Thus, muscle mass and force-producing capacity of EDL and soleus muscles from old rats treated with fenoterol was equivalent to, or greater than, untreated adult rats.
  • The increase in mass and strength was attributed to a non-selective increase in the cross-sectional area of all muscle fibre types, in both the EDL and soleus.
  • Fenoterol treatment caused a small increase in fatiguability due to a decrease in oxidative metabolism in both EDL and soleus muscles, with some cardiac hypertrophy.
  • Nevertheless, our results demonstrate that fenoterol is a powerful anabolic agent that can restore muscle mass and strength in old rats, and provide preliminary evidence of therapeutic potential for age-related muscle wasting and weakness.
  • [MeSH-major] Adrenergic beta-2 Receptor Agonists. Adrenergic beta-Agonists / therapeutic use. Aging / drug effects. Muscle Weakness / drug therapy. Muscle, Skeletal / drug effects
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Fenoterol / pharmacology. Fenoterol / therapeutic use. Male. Muscle Fatigue / drug effects. Muscle Fatigue / physiology. Rats. Rats, Inbred F344. Receptors, Adrenergic, beta-2 / physiology

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15603-7 [9861016.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2002 Aug;132(4):699-721 [12095857.001]
  • [Cites] Clin Sci (Lond). 2000 Mar;98(3):339-47 [10677393.001]
  • [Cites] J Physiol. 2002 Aug 15;543(Pt 1):169-76 [12181289.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Dec;283(6):R1386-94 [12388476.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2263-72 [12466140.001]
  • [Cites] Biosci Rep. 1984 Jan;4(1):83-91 [6141823.001]
  • [Cites] Am J Physiol. 1985 Mar;248(3 Pt 1):C265-70 [3976876.001]
  • [Cites] Histochem J. 1988 Apr;20(4):230-43 [3209423.001]
  • [Cites] J Physiol. 1988 Oct;404:71-82 [3253447.001]
  • [Cites] Metabolism. 1991 Aug;40(8):855-60 [1861634.001]
  • [Cites] J Am Geriatr Soc. 1993 Feb;41(2):149-52 [8426037.001]
  • [Cites] J Histochem Cytochem. 1993 May;41(5):733-43 [8468455.001]
  • [Cites] Clin Sci (Lond). 1993 Jun;84(6):651-4 [8334811.001]
  • [Cites] Br J Pharmacol. 1993 Aug;109(4):1157-63 [8104645.001]
  • [Cites] Med Sci Sports Exerc. 1994 Apr;26(4):432-9 [8201898.001]
  • [Cites] Br J Pharmacol. 1994 Mar;111(3):866-72 [7912629.001]
  • [Cites] Metabolism. 1994 Sep;43(9):1119-25 [7916118.001]
  • [Cites] Prog Neurobiol. 1995 Apr;45(5):397-458 [7617890.001]
  • [Cites] J Am Geriatr Soc. 1995 Aug;43(8):899-901 [7636099.001]
  • [Cites] J Anim Sci. 1995 Jun;73(6):1754-65 [7673070.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 1995 Nov;50 Spec No:91-5 [7493226.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 1995 Nov;50 Spec No:124-9 [7493205.001]
  • [Cites] Am J Physiol. 1996 Feb;270(2 Pt 2):R462-8 [8779880.001]
  • [Cites] J Physiol. 1996 Jun 1;493 ( Pt 2):543-52 [8782115.001]
  • [Cites] Muscle Nerve. 1997 Jun;20(6):679-90 [9149074.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1661-7 [9177359.001]
  • [Cites] Aging (Milano). 1997 Feb-Apr;9(1-2):153-8 [9177599.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1273-82 [9502768.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Jul;279(1):E188-95 [10893339.001]
  • [Cites] J Appl Physiol (1985). 2000 Aug;89(2):606-12 [10926644.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2000 Sep;92(1):7-12 [10986428.001]
  • [Cites] Drugs Aging. 2000 Oct;17(4):303-16 [11087008.001]
  • [Cites] Br J Sports Med. 2000 Dec;34(6):412-3 [11131226.001]
  • [Cites] J Lab Clin Med. 2001 Apr;137(4):231-43 [11283518.001]
  • [Cites] J Physiol. 2001 Sep 1;535(Pt 2):591-600 [11533147.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):513-23 [11836279.001]
  • [Cites] J Appl Physiol (1985). 2002 Mar;92(3):941-8 [11842024.001]
  • [Cites] Prog Neurobiol. 2002 Feb;66(2):61-79 [11900882.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):1966-72 [10372695.001]
  • (PMID = 14617677.001).
  • [ISSN] 0022-3751
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-2 Receptor Agonists; 0 / Adrenergic beta-Agonists; 0 / Receptors, Adrenergic, beta-2; 22M9P70OQ9 / Fenoterol
  • [Other-IDs] NLM/ PMC1664816
  •  go-up   go-down


5. Zicha J, Dobesová Z, Kunes J: Late blood pressure reduction in SHR subjected to transient captopril treatment in youth: possible mechanisms. Physiol Res; 2008;57(3):495-8
Hazardous Substances Data Bank. CAPTOPRIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late blood pressure reduction in SHR subjected to transient captopril treatment in youth: possible mechanisms.
  • Our study tried to elucidate the mechanisms responsible for long-term reduction of blood pressure (BP) in SHR subjected to early transient captopril treatment.
  • Adult untreated SHR aged 30-34 weeks were compared with animals subjected to chronic captopril treatment for 6 weeks either in youth (between 4 and 10 weeks of age) or in adulthood (between 24 and 30 weeks of age).
  • Antihypertensive effects of captopril were more pronounced in young than adult SHR.
  • The magnitude of nifedipine-sensitive component of sympathetic vasoconstriction is decisive for BP maintenance not only in untreated SHR but also in SHR during active captopril treatment by or after its withdrawal.

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18597587.001).
  • [ISSN] 0862-8408
  • [Journal-full-title] Physiological research
  • [ISO-abbreviation] Physiol Res
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antihypertensive Agents; 0 / Vasodilator Agents; 9G64RSX1XD / Captopril; I9ZF7L6G2L / Nifedipine
  •  go-up   go-down


6. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia; 2002 Jul;16(7):1259-66
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
  • In order to improve the disappointing prognosis of adult patients with acute lymphoblastic leukemia (ALL), we applied similar induction therapy as that used for acute myeloid leukemia (AML), ie frequent administration of doxorubicin (DOX).
  • From December 1993 to February 1997, 285 untreated adult patients with de novo ALL were entered.
  • Among CR patients under 40 years old, the 6-year survival was not different between the allocated related allo-BMT group (34 patients) and the allocated chemotherapy group (108 patients).
  • However, among patients with Ph-positive ALL, the survival of patients who actually received allo-BMT was superior to that of patients who received chemotherapy (P = 0.046).
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Doxorubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Asparaginase / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Humans. Prednisolone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Homologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12094249.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


7. Bhutani M, Kumar L, Vora A, Bhardwaj N, Pathak AK, Singh R, Kochupillai V: Randomized study comparing 4'-epi-doxorubicin (epirubicin) versus doxorubicin as a part of induction treatment in adult acute lymphoblastic leukemia. Am J Hematol; 2002 Dec;71(4):241-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized study comparing 4'-epi-doxorubicin (epirubicin) versus doxorubicin as a part of induction treatment in adult acute lymphoblastic leukemia.
  • Doxorubicin or daunorubicin are routinely used to induce remission in acute lymphoblastic leukemia (ALL).
  • This randomized study was undertaken to compare the relative efficacy of epirubicin vs. doxorubicin as part of induction chemotherapy in adult ALL.
  • Between January 1990 and June 1998, 79 previously untreated adult ALL patients (age 11-55 years, median 20 years) were randomized to receive either doxorubicin (Group A, n = 39) or epirubicin (Group B, n = 40) as a part of induction therapy.
  • The induction treatment was followed by identical consolidation and maintenance therapy.
  • The two groups were compared as regards pretherapy clinical and laboratory parameters, dose intensity of therapy, therapeutic efficacy, myelotoxicity, and survival.
  • From this study epirubicin appears as effective as doxorubicin as part of induction therapy for adult ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Recurrence. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12447951.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin
  •  go-up   go-down


8. Wiernik PH, Cassileth PA, Leong T, Hoagland HC, Bennett JM, Paietta E, Oken MM, Eastern Cooperative Oncology Group Study: A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486). Leuk Lymphoma; 2003 Sep;44(9):1515-21
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
  • In this study of previously untreated adult acute lymphocytic leukemia (ALL) performed by the Eastern Cooperative Oncology Group, patients were randomized to induction therapy with either DVP (daunorubicin 45 mg/m2 daily, days 1, 2 and 3; prednisone 60 mg/m2 daily orally days 1-35; and vincristine 2 mg intravenously on days 1, 8, 15 and 22) or DATVP (daunorubicin 60 mg/m2 daily, days 1, 2 and 3; cytarabine 25 mg/m2 intravenous bolus followed by 200 mg/m2 daily as a continuous infusion on days 1-5; 6-thioguanine 100 mg/m2 orally every 12 h on days 1-5; vincristine 2 mg intravenously on days 1 and 8; and prednisone 60 mg/m2/day orally, days 1-7.
  • Complete responders to both regimens received the same post-remission therapy, which consisted of a single course of cytarabine 3 gm/m2 infused over 1 h every 12 h for 12 doses.
  • One month later those patients still in remission received six cycles of consolidation therapy with MACHO (cyclophosphamide 650 mg/m2, doxorubicin 40 mg/m2 vincristine 2mg all intravenously on day 1 with prednisone 100 mg/m2 orally daily on days 1-5.
  • Intensification of treatment for adults with ALL may not improve outcome.
  • Progress in the treatment of adults with ALL will require the identification of new agents for this neoplasm.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Life Tables. Male. Methotrexate / administration & dosage. Middle Aged. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Survival Analysis. Thioguanine / administration & dosage. Thioguanine / adverse effects. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565653.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 11083; United States / NCI NIH HHS / CA / CA 13650; United States / NCI NIH HHS / CA / CA 14958; United States / NCI NIH HHS / CA / CA 21115; United States / NCI NIH HHS / CA / CA 23318; United States / NCI NIH HHS / CA / CA 66636; United States / NCI NIH HHS / CA / CA91151
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; FTK8U1GZNX / Thioguanine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; DATOP protocol; DVP (daunomycin); MACHO protocol
  •  go-up   go-down


9. Choudhury M, Needleman I, Gillam D, Moles DR: Systemic and local antimicrobial use in periodontal therapy in England and Wales. J Clin Periodontol; 2001 Sep;28(9):833-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic and local antimicrobial use in periodontal therapy in England and Wales.
  • BACKGROUND/AIMS: The aim of this study was to investigate antimicrobial use during periodontal therapy in dental practice in England & Wales.
  • We designed and piloted a questionnaire to evaluate both systemic and local antibiotic use with periodontal therapy as well as factors affecting their prescription.
  • Systemic antibiotics were used by 7.4% Periodontal Society members and 18.4% GDP for untreated adult periodontitis patients (p<0.001).
  • Regarding local antimicrobials, usage for untreated adult periodontitis was Periodontal Society 8.9% and GDP 5.4%.
  • Higher usage of local antimicrobials was found both for the treatment of recurrent pocketing in adult periodontitis (Periodontal Society 26.3%, GDP 14.8%, p<0.014) and refractory periodontitis (Periodontal Society 30.8%, GDP 15.2%, p<0.001).
  • 33% of Periodontal Society members and 3.8% of GDP spent at least 45 min per quadrant on root planing and Periodontal Society members had a greater exposure to lectures on both systemic and local drug therapy compared with GDP (p<0.001).
  • CONCLUSIONS: Systemic antimicrobial use was infrequent for adult periodontitis and generally in line with current recommendations for other disease types.
  • Whilst local antimicrobial therapy for periodontitis was not widespread, a substantial minority of dentists use this form of therapy and most believe that it is more effective than root debridement alone.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Drug Utilization / statistics & numerical data. Periodontal Diseases / drug therapy. Periodontics / standards
  • [MeSH-minor] Adult. Dentistry / standards. England. Female. Guideline Adherence. Humans. Male. Middle Aged. Surveys and Questionnaires. Wales

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11493352.001).
  • [ISSN] 0303-6979
  • [Journal-full-title] Journal of clinical periodontology
  • [ISO-abbreviation] J. Clin. Periodontol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


10. Hołowiecki J, Giebel S, Krzemień S, Krawczyk-Kuliś M, Jagoda K, Kopera M, Hołowiecka B, Grosicki S, Hellmann A, Dmoszyńska A, Paluszewska M, Robak T, Konopka L, Maj S, Wojnar J, Wojciechowska M, Skotnicki A, Baran W, Cioch M: G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk Lymphoma; 2002 Feb;43(2):315-25
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study.
  • Sixty-four untreated adult acute lymphoblastic leukemia (ALL) patients were randomized to receive chemotherapy alone, n = 31 or chemotherapy and granulocyte colony stimulating factor (G-CSF), n = 33.
  • The beneficial influence of G-CSF administered in time-sequenced fashion on survival needs further confirmation.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Agranulocytosis / prevention & control. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Drug Administration Schedule. Female. Humans. Infection. Length of Stay. Male. Middle Aged. Remission Induction / methods. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999563.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


11. Jenkinson MD, Smith TS, Haylock B, Husband D, Shenoy A, Vinjamuri S, Walker C, Pietronigro D, Warnke PC: Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. J Neurooncol; 2010 Aug;99(1):103-13
Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.
  • DTI-015 (BCNU dissolved in ethanol) utilizes solvent facilitated perfusion (SFP) for intratumoral drug delivery.
  • Pre- and post DTI-015 injection neuro-imaging included computed tomography (CT) cerebral blood flow and volume, glucose and thallium single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carmustine / therapeutic use. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Aged. Brain Mapping. Cerebrovascular Circulation / drug effects. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Injections, Intramuscular / methods. Karnofsky Performance Status. Magnetic Resonance Imaging / methods. Male. Middle Aged. Thallium. Tomography Scanners, X-Ray Computed. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2000 Jan;2(1):45-59 [11302254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1351-6 [2689399.001]
  • [Cites] J Neurooncol. 2003 May;62(3):251-8 [12777076.001]
  • [Cites] Neurosurg Focus. 2003 Feb 15;14(2):e2 [15727423.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7182-91 [15534091.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):373-6 [12719953.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):267-75 [15739554.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1276-80 [3948112.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):9-16 [12659665.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] J Cereb Blood Flow Metab. 1991 Sep;11(5):753-61 [1874807.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):17-22 [12659666.001]
  • [Cites] Stroke. 1977 Jan-Feb;8(1):51-7 [13521.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Can J Neurol Sci. 1999 Feb;26(1):18-22 [10068802.001]
  • [Cites] CNS Drugs. 2001;15(9):719-43 [11580310.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):379-80 [11565856.001]
  • [Cites] Neuroradiology. 2006 Oct;48(10):703-13 [16937145.001]
  • [Cites] Ann Neurol. 2005 Jan;57(1):136-9 [15622544.001]
  • [Cites] Neurosurgery. 1988 Mar;22(3):465-73 [2452376.001]
  • [Cites] Neuro Oncol. 2001 Oct;3(4):241-5 [11584893.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4489-92 [3396000.001]
  • [Cites] Magn Reson Imaging. 2007 Apr;25(3):303-10 [17371718.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):225-38 [15980973.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):402-8 [16484419.001]
  • [Cites] J Nucl Med. 1998 May;39(5):786-90 [9591575.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7852-9 [15585617.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):1-8 [11763417.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Mutat Res. 1990 Nov-Dec;233(1-2):117-26 [2233793.001]
  • [Cites] Acta Oncol. 1995;34(3):335-8 [7779419.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):99-104 [7721644.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 20063175.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AD84R52XLF / Thallium; U68WG3173Y / Carmustine
  •  go-up   go-down


12. Rödel S, Engert A, Diehl V, Reiser M: Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. Leuk Lymphoma; 2005 Dec;46(12):1729-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study.
  • The aim of the present study was to evaluate the feasibility and efficacy of the intensified induction chemotherapy regimen ACOMED for patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Untreated adult patients with aggressive NHL, presenting with Ann Arbour stage II-IV disease or stage I with bulky disease, and with at least one of the following risk factors: age > 60 years, advanced disease, elevated serum lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) performance status >or= 2, presence of extranodal sites of disease and bulky disease, were treated with the ACOMED regimen consisting of 4-6 cycles of adriamycin 25 mg/m(2) i.v. on days 4-5, cyclophosphamide 250 mg/m(2) i.v. on days 1-5, vincristine 2 mg i.v. absolute on day 1, methotrexate 500 mg/m(2) i.v. on day 1 with leucovorin-rescue after 24 h 30 mg/m(2) i.v. and 3 x 15 mg p.o., etoposide 100 mg/m(2) i.v. on days 3-5, dexamethasone 10 mg/m(2) p.o. on days 1-5 and granulocyte colony-stimulating factor support, repeated on day 21.
  • After a median observation time of 10 years and 2 months, 16/22 (73%) patients are alive in continuous complete response without evidence of any late toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Radiotherapy / adverse effects. Survival Analysis. Survivors. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353313.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


13. Sotomayor EM, Piantadosi S, Miller CB, Karp JE, Jones RJ, Rowley SD, Kaufmann SH, Braine H, Burke PJ, Gore SD: Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy. Leuk Res; 2002 May;26(5):461-71
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.
  • We report single institution outcome of brief, intensive ara-C-based chemotherapy using bone marrow transplantation as primary intensification for untreated adult patients with acute lymphoblastic leukemia (ALL).
  • Overall disease-free and overall survival were inferior to those reported with prolonged chemotherapy modeled on pediatric protocols.
  • Survival and disease-free survival were superior for patients receiving allogeneic BMT compared with chemopurged autologous transplant or maintenance chemotherapy (patients ineligible for or declining BMT).
  • Autologous BMT was not superior to chemotherapy, and appears unlikely to provide adequate curative treatment for most adult ALL patients if not followed by maintenance.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bone Marrow Transplantation. Cytarabine / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Follow-Up Studies. Humans. Middle Aged. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2002 May;26(5):473-6 [11916521.001]
  • (PMID = 11916520.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 06973; United States / NCI NIH HHS / CA / CA 15396
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


14. Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I: Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer; 2006 Sep;42(14):2303-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
  • This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas.
  • Six patients developed a DLT at dose L5, and thus the recommended dose is level 4 (i.e.
  • Five patients discontinued therapy because of toxicity, 4 of them at dose level 5.
  • In conclusion, this seems to be a feasible combination in patients with advanced soft tissue sarcomas, allowing ifosfamide to be given in a dosage similar to that used when given alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891112.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Toni TD, Recordon-Pinson P, Minga A, Ekouevi D, Bonard D, Bequet L, Huet C, Chenal H, Rouet F, Dabis F, Lafon ME, Salamon R, Masquelier B, Fleury HJ: Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses; 2003 Aug;19(8):713-7
LANL HIV Databases. LANL HIV Databases .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study.
  • A total of 107 HIV-1 isolates from untreated adult patients recruited in Abidjan, CMte d'Ivoire, in 2001 and 2002 were sequenced in the env, reverse transcriptase (RT), and protease genes.
  • The results show that CRF02_AG is still predominant in this west African population; key mutations of resistance to antiretroviral drugs (NRTI, NNRTI, and PIs) were detected in 5.6% of the patients.
  • [MeSH-major] Drug Resistance, Viral / genetics. HIV Protease / genetics. HIV Reverse Transcriptase / genetics. HIV-1 / genetics
  • [MeSH-minor] Adult. Anti-HIV Agents / pharmacology. Cote d'Ivoire / epidemiology. DNA, Viral / analysis. Female. Gene Transfer, Horizontal. Genetics, Population. HIV Infections / drug therapy. Humans. Male. Microbial Sensitivity Tests. Mutation

  • Stanford HIV Drug Resistance Database. gene/protein/disease-specific - Stanford HIV Drug Resistance Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506786.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA, Viral; EC 2.7.7.49 / HIV Reverse Transcriptase; EC 3.4.23.- / HIV Protease
  •  go-up   go-down


16. Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R: Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol; 2010 Jan;91(1):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
  • A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG).
  • Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B).
  • However, among patients enrolled in this trial, intensive chemotherapy did not produce better survival than low-dose chemotherapy.
  • In conclusion, it is necessary to introduce the first line therapy excluding the chemotherapy that can prolong survival in patients with high-risk MDS and MDS-AML.
  • [MeSH-major] Aclarubicin / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Female. Humans. Japan. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 2005;56:1-16 [15660498.001]
  • [Cites] Blood. 2004 Jul 15;104(2):579-85 [15039286.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):599-602 [16690517.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):785-98 [18471050.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1357-62 [17508002.001]
  • [Cites] Int J Hematol. 2000 Aug;72(2):151-6 [11039662.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1024-8 [19185917.001]
  • [Cites] Leukemia. 1995 Jan;9(1):10-4 [7531259.001]
  • [Cites] Int J Hematol. 2000 Aug;72(2):200-5 [11039669.001]
  • [Cites] Br J Haematol. 1982 Jun;51(2):189-99 [6952920.001]
  • [Cites] Leuk Res. 1992;16(1):109-15 [1732663.001]
  • [Cites] Leukemia. 2005 Mar;19(3):396-401 [15674354.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):345-52 [17559141.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62 [17382251.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Dec;40(3):229-38 [11738946.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Ann Hematol. 1992 Oct;65(4):162-8 [1420504.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):93-5 [10651730.001]
  • [Cites] Blood. 2008 Aug 1;112(3):895-902 [18497321.001]
  • (PMID = 20047095.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 74KXF8I502 / Aclarubicin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


17. Giardino L, Giuliani A, Battaglia A, Carfagna N, Aloe L, Calza' L: Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion). Neuroscience; 2002;109(3):487-97
Hazardous Substances Data Bank. COLCHICINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Attempts to prevent age-associated cholinergic vulnerability and deterioration therefore represent a crucial point for pharmacotherapy in the elderly.
  • Colchicine induces a rapid and substantial down-regulation of choline acetyltransferase messenger RNA level in the basal forebrain in untreated adult, middle-aged and old rats.
  • Based on the present findings, nicergoline proved to be an effective drug for preventing neuronal vulnerability due to experimentally induced nerve growth factor deprivation.
  • [MeSH-major] Aging / drug effects. Cholinergic Fibers / drug effects. Nerve Degeneration / drug therapy. Nerve Growth Factor / deficiency. Neuroprotective Agents / pharmacology. Nicergoline / pharmacology. Nootropic Agents / pharmacology. Septal Nuclei / drug effects
  • [MeSH-minor] Animals. Choline O-Acetyltransferase / genetics. Cognition Disorders / drug therapy. Cognition Disorders / metabolism. Cognition Disorders / physiopathology. Colchicine / pharmacology. Down-Regulation / drug effects. Down-Regulation / physiology. Male. Nitric Oxide Synthase / genetics. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Rats

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11823061.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 0 / Nootropic Agents; 0 / RNA, Messenger; 9061-61-4 / Nerve Growth Factor; EC 1.14.13.39 / Nitric Oxide Synthase; EC 2.3.1.6 / Choline O-Acetyltransferase; JCV8365FWN / Nicergoline; SML2Y3J35T / Colchicine
  •  go-up   go-down


18. Carli L, Montecucco C, Rossetto O: Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve; 2009 Sep;40(3):374-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg.
  • Botulinum neurotoxin type-A (BoNT/A) is very effective in the therapy of a wide range of human syndromes characterized by hyperactivity of peripheral cholinergic nerve terminals.
  • Little diffusion of this toxin from the site of injection is commonly observed, but even minor changes in this property would greatly affect the validity of the treatment.
  • Different pharmacological formulations of BoNT/A are available, and they may have different diffusion characteristics due to protein complex size, product format, and pharmacological properties.
  • N-CAM is a membrane glycoprotein that accumulates on muscle fibers after denervation and is not expressed in untreated adult muscle.
  • [MeSH-major] Botulinum Toxins, Type A / metabolism. Botulinum Toxins, Type A / pharmacology. Hindlimb. Muscle, Skeletal / drug effects. Muscle, Skeletal / metabolism. Neuromuscular Agents / metabolism. Neuromuscular Agents / pharmacology
  • [MeSH-minor] Animals. Chemistry, Pharmaceutical / classification. Gene Expression Regulation / drug effects. Injections, Intramuscular / methods. Male. Mice. Muscle Weakness / chemically induced. Neural Cell Adhesion Molecules / metabolism. Neurologic Examination / methods. Time Factors. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Botox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618426.001).
  • [ISSN] 0148-639X
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP06133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neural Cell Adhesion Molecules; 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


19. Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Michaux L, Sonet A, Bosly A, Doyen C, Mineur P, André M, Straetmans N, Coche E, Venet C, Duprez T, Ferrant A: Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia; 2000 Jun;14(6):1136-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
  • Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
  • Twenty-six patients received 68 cycles of chemotherapy.
  • Acute neutropenia was the dose-limiting toxicity of this regimen, which was otherwise well tolerated.
  • Given the response rate observed, further studies of this regimen are warranted in untreated patients, in particular with chronic lymphocytic leukemia and with Waldenström macroglobulinemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cladribine / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Male. Middle Aged. Survival Analysis


20. Robak T: Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs; 2005;19(1):9-22
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in the treatment of chronic lymphocytic leukemia.
  • Alemtuzumab is a humanized therapeutic monoclonal antibody (MAb) that recognizes the CD52 antigen, expressed on normal and neoplastic lymphocytes, monocytes, and natural killer cells.
  • In 2001, alemtuzumab was approved in the US and Europe to treat B-cell chronic lymphocytic leukemia (CLL) that had been treated previously with alkylating agents and was refractory to fludarabine.
  • In heavily pretreated patients this MAb is able to produce response rates of about 40%, and in symptomatic, previously untreated patients response rates of more than 80% can be achieved.
  • Moreover its in vivo use before or after SCT may also potentially result in depletion of residual leukemia cells, especially in the autologous setting.
  • Adverse events associated with alemtuzumab include acute first-dose reaction, hematologic toxicity, and infectious complications.
  • However, in a significant percentage of patients, cytomegalovirus reactivation occurs during alemtuzumab therapy, and routine weekly monitoring with the polymerase chain reaction methodology is indicated.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / adverse effects. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Drug Administration Schedule. Half-Life. Humans. Infusions, Intravenous. Middle Aged. Rituximab. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691213.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 99
  •  go-up   go-down


21. Usuki K, Adachi Y, Kazama K, Iki S, Urabe A: [Treatment of adult acute lymphoblastic leukemia by KHALL-93--long-term outcome]. Gan To Kagaku Ryoho; 2000 Aug;27(9):1397-402
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult acute lymphoblastic leukemia by KHALL-93--long-term outcome].
  • Twelve previously untreated adult patients with acute lymphoblastic leukemia were treated with a KHALL-93 regimen.
  • These results indicate that a KHALL-93 regimen is an effective therapy for adult acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969595.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


22. Sagripanti A, Sarteschi LM, Carpi A: The management of idiopathic thrombotic microangiopathy. Changing trends. Biomed Pharmacother; 2000 Oct;54(8-9):423-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over 90% of the reported cases in the adult, when untreated, have progressed to death within three months of diagnosis.
  • Indeed, improved survival is the most striking feature of adult thrombotic microangiopathy compared to some decades ago.
  • In the present article we will focus on the evolving concepts able to exert a considerable impact in the management of the adult idiopathic form of thrombotic microangiopathy.
  • [MeSH-major] Hemolytic-Uremic Syndrome / therapy. Multiple Organ Failure / therapy. Plasma Exchange. Platelet Aggregation Inhibitors / therapeutic use. Purpura, Thrombotic Thrombocytopenic / therapy
  • [MeSH-minor] Adult. Humans. Iloprost / pharmacology. Iloprost / therapeutic use. Platelet Aggregation / drug effects. Platelet Aggregation / physiology. Thrombosis / complications. Thrombosis / diagnosis. Thrombosis / therapy

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100895.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; JED5K35YGL / Iloprost
  • [Number-of-references] 68
  •  go-up   go-down


23. Goodman DW: The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract; 2007 Sep;13(5):318-27
Hazardous Substances Data Bank. ATOMOXETINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although treatments are available for adult ADHD, many patients never receive an accurate diagnosis that would afford them appropriate therapeutic intervention.
  • If left untreated, adult ADHD can cause significant personal, social, and economic burdens that can have a negative impact on overall quality of life.
  • Currently available treatments for ADHD in adults are also reviewed.
  • [MeSH-minor] Achievement. Adult. Age Factors. Amphetamine / therapeutic use. Atomoxetine Hydrochloride. Cognitive Therapy. Combined Modality Therapy. Comorbidity. Disease Progression. Female. Health Care Costs. Humans. Impulsive Behavior / diagnosis. Impulsive Behavior / psychology. Male. Mental Disorders / diagnosis. Mental Disorders / drug therapy. Mental Disorders / epidemiology. Methylphenidate / therapeutic use. Propylamines / therapeutic use. Quality of Life. Sex Distribution. Social Adjustment. Substance-Related Disorders / diagnosis. Substance-Related Disorders / epidemiology. Substance-Related Disorders / psychology

  • Genetic Alliance. consumer health - Attention Deficit Disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890980.001).
  • [ISSN] 1527-4160
  • [Journal-full-title] Journal of psychiatric practice
  • [ISO-abbreviation] J Psychiatr Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Propylamines; 207ZZ9QZ49 / Methylphenidate; 57WVB6I2W0 / Atomoxetine Hydrochloride; CK833KGX7E / Amphetamine
  • [Number-of-references] 74
  •  go-up   go-down


24. Gutiérrez LP, Kołtowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, Westberg B, Luger A: Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf; 2008 Jan;17(1):90-102
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Analysis of data collected prospectively for a pharmacoepidemiological registry--KIMS (Pfizer International Metabolic Database)--in assessing long-term clinical and safety outcomes of GH treatment (Genotropin) in patients with GH deficiency.
  • The study was based on 11,374 treated (40,000 patient-years of observation) and 263 untreated adult GH deficient patients from 30 countries, in whom background characteristics, clinical values such as lipids and body composition, quality of life (QoL) and GH dosage as well as safety profile were evaluated.
  • RESULTS: The study depicts the clinical picture of adult patients with GH deficiency managed in current clinical settings.
  • The 31 out of 36 KIMS papers were cited 544 times, in 125 different journals.
  • CONCLUSIONS: These findings and the further insight into the response to GH replacement therapy show that the registry methodology is valuable for filling the gaps of information in evidence-based medicine that cannot be addressed by clinical trials.
  • [MeSH-major] Hormone Replacement Therapy. Human Growth Hormone / deficiency. Human Growth Hormone / therapeutic use. Hypopituitarism / drug therapy. Registries
  • [MeSH-minor] Adult. Body Composition / drug effects. Cholesterol / blood. Evidence-Based Medicine. Female. Humans. Male. Prospective Studies. Quality of Life. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957812.001).
  • [ISSN] 1053-8569
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


25. Santagostino E, De Filippi F, Rumi MG, Rivi M, Colombo M, Mannucci PM, Hepatitis Study Group of the Association of Italian Hemophilia Centers: Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion; 2004 May;44(5):790-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients.
  • BACKGROUND: In a recent randomized controlled study, only a minority (15%) of adult hemophiliacs with chronic HCV achieved a sustained virologic response to treatment with interferon (IFN) and ribavirin given at standard doses.
  • STUDY DESIGN AND METHODS: Whether the therapeutic response might be improved in these patients by increasing the doses of IFN was evaluated.
  • Thirty-four previously untreated, adult hemophiliacs with chronic HCV but negative for HIV were investigated.
  • RESULTS: A total of 33 patients (97%) completed the study; one patient withdrew because of treatment-related symptoms.
  • Treatment dosage had to be reduced in 20 patients (59%).
  • CONCLUSIONS: High-dose IFN therapy plus ribavirin provided high rates of sustained virologic responses in adult hemophiliacs with chronic HCV, even if side-effects led to dose reduction in half of these patients.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hemophilia A / virology. Hepacivirus / drug effects. Hepatitis C, Chronic / drug therapy. Interferons / administration & dosage. Ribavirin / administration & dosage
  • [MeSH-minor] Adult. Cohort Studies. Drug Therapy, Combination. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hemophilia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15104664.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 49717AWG6K / Ribavirin; 9008-11-1 / Interferons
  •  go-up   go-down


26. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol; 2002 Sep 15;20(18):3878-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
  • PURPOSE: Patients with chronic lymphocytic leukemia (CLL) may have disease transformation to non-Hodgkin's lymphoma or prolymphocytic leukemia; however, development of therapy-related acute myeloid leukemia (t-AML) is unusual.
  • PATIENTS AND METHODS: A total of 544 previously untreated B-cell CLL patients were enrolled onto a randomized intergroup study comparing treatment with chlorambucil, fludarabine, or fludarabine plus chlorambucil.
  • RESULTS: With a median follow-up of 4.2 years, six patients (1.2%) to date have developed therapy-related myelodysplastic syndrome (t-MDS; n = 3), t-AML (n = 2), or t-MDS evolving to t-AML (n = 1), from 27 to 53 months (median, 34 months) after study entry.
  • This included five (3.5%) of 142 patients treated with fludarabine plus chlorambucil and one (0.5%) of 188 receiving fludarabine; no chlorambucil-treated patients developed t-MDS or t-AML (P =.007).
  • Response to CLL therapy was complete (n = 4) or partial remission (n = 1) and stable disease (n = 1).
  • CONCLUSION: Our findings raise the possibility that alkylator-purine analog combination therapy may increase the risk of therapy-related myeloid malignancies, which is of particular relevance with regard to ongoing trials using these combination therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow / pathology. Chlorambucil / administration & dosage. Chlorambucil / adverse effects. Chromosome Aberrations. Clinical Trials, Phase III as Topic. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Oct 1;21(19):3709; author reply 3709-10 [14512411.001]
  • (PMID = 12228208.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32102
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


27. Franzin L, Pennazio M, Cabodi D, Paolo Rossini F, Gioannini P: Clarithromycin and amoxicillin susceptibility of Helicobacter pylori strains isolated from adult patients with gastric or duodenal ulcer in Italy. Curr Microbiol; 2000 Feb;40(2):96-100
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clarithromycin and amoxicillin susceptibility of Helicobacter pylori strains isolated from adult patients with gastric or duodenal ulcer in Italy.
  • Helicobacter pylori strains, isolated from 100 gastric biopsies from 49 previously untreated adult patients with endoscopy and histology-confirmed gastric or duodenal ulcer, were tested for in vitro antimicrobial susceptibility.
  • Strains were isolated from biopsies of 75.5% (37 of 49) patients before therapy and of 13.5% after therapy.
  • [MeSH-major] Amoxicillin / pharmacology. Anti-Bacterial Agents / pharmacology. Clarithromycin / pharmacology. Duodenal Ulcer / microbiology. Helicobacter pylori / drug effects. Penicillins / pharmacology. Stomach Ulcer / microbiology
  • [MeSH-minor] Adolescent. Adult. Aged. Colony Count, Microbial. Drug Resistance, Microbial. Female. Humans. Italy. Male. Microbial Sensitivity Tests. Middle Aged

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10594221.001).
  • [ISSN] 0343-8651
  • [Journal-full-title] Current microbiology
  • [ISO-abbreviation] Curr. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Penicillins; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin
  •  go-up   go-down


28. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E: Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs; 2006 Mar;24(2):159-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.
  • Untreated adult patients with measurable MRC were treated with MG98 at a dose of 360 mg/m2 via 2-h iv infusion twice weekly for three consecutive weeks out of four.
  • Seventeen eligible patients received a median of two cycles of treatment (range, 1-7), and no objective responses were seen.
  • No conclusive pattern of decreased DNMT1 activity in PBMCs was detected post MG98 treatment.
  • The lack of objective responses observed may be explained by a lack of target effect or the choice of tumor type.
  • Transaminitis was observed in patients with prior nephrectomy and appeared to be associated with altered drug exposure in these patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Oligodeoxyribonucleotides / therapeutic use. Repressor Proteins / antagonists & inhibitors. Thionucleotides / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Canada. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. RNA, Messenger / blood

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1594-8 [2418016.001]
  • [Cites] Invest New Drugs. 2003 Feb;21(1):85-97 [12795533.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):672-83 [12424069.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] J Urol. 2002 Jul;168(1):239-47 [12050550.001]
  • [Cites] J Cell Biochem Suppl. 2000;Suppl 35:78-83 [11389535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7504-9 [11390984.001]
  • [Cites] Ann Oncol. 2003 May;14(5):766-74 [12702532.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 [7937876.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3854-61 [15897586.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10 (21):7244-51 [15534098.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):14-7 [10023944.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3920-7 [11751483.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):679-83 [11895895.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1265-71 [9562580.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2859-67 [10561363.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5048-57 [15297406.001]
  • (PMID = 16502349.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DMAP1 protein, human; 0 / MG 98 phosphorothioate antisense oligodeoxynucleotide; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Thionucleotides
  •  go-up   go-down


29. Zucchini S, Pirazzoli P, Baronio F, Gennari M, Bal MO, Balsamo A, Gualandi S, Cicognani A: Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab; 2006 Nov;91(11):4271-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency.
  • CONTEXT: GH replacement therapy in GH-deficient (GHD) patients is usually continued until adult height despite the fact that most of these subjects display a normal secretion when retested at the end of growth.
  • Puberty is the most likely time for normalization of GH secretion.
  • PATIENTS AND INTERVENTION: Sixty-nine subjects (40 male, 29 female) with a diagnosis before puberty of isolated GHD by means of arginine and l-dopa tests were reevaluated with the same tests after at least 2 yr of therapy and after puberty onset.
  • If GH peak at retesting was more than 10 microg/liter, therapy was withdrawn.
  • MAIN OUTCOME MEASURES: Percentage and characteristics of normalized subjects at retesting, outcome of treatment in the subjects treated or untreated to adult height, and factors predictive of growth outcome were measured.
  • Mean adult height was 165.1 +/- 4.5 cm in the male group treated until adult height vs. 164.0 +/- 3.4 cm in the group who suspended therapy at retesting.
  • Mean adult height was 153.2 +/- 4.1 cm in the female group treated until adult height vs. 152.9 +/- 5.2 cm in the group that suspended therapy at retesting.
  • As regards the parameters expressing the final outcome, the only difference was found in the mean increment adult height-target height sd score in favor of the male group treated until adult height.
  • In both sexes, therapy duration and GH levels at diagnosis and at retesting were unrelated to adult height parameters and to height increments during the period of observation.
  • The withdrawal of GH therapy in these subjects after retesting was not associated with a catch down growth, and they obtained an adult height similar to those obtained by the GHD subjects treated until adult height.
  • It seems convenient, in subjects with nonsevere GHD, to retest GH secretion at midpuberty and to withdraw treatment for the subjects that are no longer deficient.
  • [MeSH-major] Body Height / physiology. Human Growth Hormone / blood. Puberty / blood. Withholding Treatment
  • [MeSH-minor] Adolescent. Age Determination by Skeleton. Child. Dwarfism, Pituitary / blood. Dwarfism, Pituitary / diagnosis. Dwarfism, Pituitary / drug therapy. Female. Follow-Up Studies. Gonadal Steroid Hormones / blood. Growth Disorders / blood. Growth Disorders / diagnosis. Growth Disorders / drug therapy. Hematologic Tests. Hormone Replacement Therapy. Humans. Male. Models, Statistical. Regression Analysis. Sex Characteristics. Statistics as Topic

  • Genetic Alliance. consumer health - Adult Growth Hormone Deficiency.
  • Genetic Alliance. consumer health - Growth Hormone Deficiency.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912138.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


30. Eisig JN, André SB, Silva FM, Hashimoto C, Moraes-Filho JP, Laudanna AA: The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy. Arq Gastroenterol; 2003 Jan-Mar;40(1):55-60
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy.
  • AIM: We studied the impact of the antimicrobial resistance on the efficacy of a short course pantoprazole based triple therapy in a single-center pilot study.
  • METHODS: Forty previously untreated adult patients (age range 20 to 75 years, 14 males) infected with Helicobacter pylori and with inactive or healing duodenal ulcer disease were assigned in this open cohort study to 1 week twice daily treatment with pantoprazole 40 mg, plus clarithromycin 250 mg and metronidazole 400 mg.
  • Helicobacter pylori was assessed at entry and 50 3 days after the end of treatment by rapid urease test, culture and histology of gastric biopsies.
  • Susceptibility of Helicobacter pylori to clarithromycin and metronidazole was determined before treatment with the disk diffusion test.
  • RESULTS: One week treatment and follow up were complete in all patients.
  • CONCLUSIONS: A short course of pantoprazole-based triple therapy is well tolerated and effective in eradicating Helicobacter pylori.
  • The baseline metronidazole resistance may be a significant limiting factor in treatment success.
  • [MeSH-major] Anti-Ulcer Agents / therapeutic use. Benzimidazoles / therapeutic use. Drug Resistance, Bacterial. Duodenal Ulcer / drug therapy. Helicobacter Infections / drug therapy. Helicobacter pylori / drug effects. Sulfoxides / therapeutic use
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Anti-Infective Agents / therapeutic use. Clarithromycin / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Metronidazole / therapeutic use. Middle Aged. Omeprazole / analogs & derivatives. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534667.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Ulcer Agents; 0 / Benzimidazoles; 0 / Sulfoxides; 140QMO216E / Metronidazole; D8TST4O562 / pantoprazole; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  •  go-up   go-down


31. Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K, Polish Adult Leukemia Group (PALG): Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia; 2004 May;18(5):989-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
  • To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m2/day, days 1-3; cytarabine (AraC) 200 mg/m2/day, days 1-7; cladribine (2-CdA) 5 mg/m2/day, days 1-5, 400 untreated adult acute myeloid leukemia patients (including 63 with preceding myelodysplastic syndrome), aged 45 (16-60) years were randomized to either DAC-7 (n=200) or DA-7 (without 2-CdA, n=200).
  • Median hospitalization time during the induction was 7 days shorter for DAC-7 compared to the DA-7 group (33 vs 40 days, P=0.002).
  • The probability of 3-year leukemia-free survival (LFS) for DAC-7 and DA-7 group equaled 43 and 34%, respectively (P=NS).
  • It shortens hospitalization time and may improve long-term survival in patients aged >40 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cladribine / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14999298.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


32. Szmigielska-Kaplon A, Smolewski P, Najder M, Robak T: Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Ann Hematol; 2002 Sep;81(9):508-13
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
  • The aim of the study was to evaluate the effect of three anthracyclines [doxorubicin (DOX), mitoxantrone (MIT), and idarubicin (IDA)] on the rate of apoptosis triggered by 2-chlorodeoxyadenosine (2-CdA) in peripheral blood mononuclear cells isolated from 52 untreated patients with B-cell chronic lymphocytic leukemia (B-CLL).
  • The cells were cultured up to 48 h in the presence of drugs alone and in the following combinations: 2-CdA+DOX, 2-CdA+MIT, and 2-CdA+IDA.
  • Combination of 2-CdA with MIT induced a similar effect, also more distinct after 48 h (median AI for 2-CdA+MIT=41.05%, median AI for MIT=16.3%, p=0.0012, and median AI for 2-CdA=22.1%, p=0.017).
  • For both combinations median AI were similar to the sum of median AI for each drug when used alone.
  • IDA in a concentration ten times lower (0.1 micro g/ml) than used before in acute leukemia cells produced high cytotoxic effects, masking the additive effect of combination with 2-CdA.
  • In conclusion; these data indicate an additive cytotoxic effect on B-CLL cells of DOX, MIT, and IDA applied in vitro with 2-CdA; all of them induced apoptosis with similar efficacy.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Cladribine / pharmacology. Leukemia, B-Cell / drug therapy. Lymphocytes / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Female. Humans. Idarubicin / pharmacology. Kinetics. Male. Middle Aged. Mitoxantrone / pharmacology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12373351.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 47M74X9YT5 / Cladribine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


33. Ramos Costa Mdo R, de Oliveira MA, Caetano LB, Santoro IL, Godoy Fernandes AL: Time required to achieve asthma control in not previously inhaled corticosteroid treated adult patients. J Asthma; 2008 Sep;45(7):579-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time required to achieve asthma control in not previously inhaled corticosteroid treated adult patients.
  • AIM: To measure the length of time needed in a structured educational training program to achieve well-controlled asthma status.
  • METHODS: This 5-month clinical trial enrolled previously untreated adult asthma patients at the Asthma Center of the President Dutra Public Hospital/Federal University of Maranhao-Brazil.
  • In the educational program, sessions covered signs and symptoms of asthma exacerbation, triggering factors, environmental control, and asthma drug effects.
  • The time required to achieve well-controlled status and the total time free of asthma symptoms were evaluated by Kaplan-Meier curves.
  • The first six-month Kaplan-Meier curve demonstrated that Class I patients had a significantly better probability of achieving well-controlled asthma than the other classes (log rang = 6.78, p = 0.03), The second 6-month Kaplan-Meier curve analyzed the total time free of asthma symptoms according to PEFR class (log rank = 11, 22 p = 0.003).
  • The time required to reach a well-controlled status was 2 or 3 months, depending on the baseline level of airway obstruction: patients in PEFR classes I and II achieved good control earlier than patients in PEFR Class III.
  • [MeSH-major] Asthma / drug therapy. Glucocorticoids / administration & dosage. Patient Education as Topic. Physician-Patient Relations
  • [MeSH-minor] Administration, Inhalation. Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Time Factors


34. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood; 2010 Apr 8;115(14):2755-62
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous observational studies suggest that rituximab may be useful in the treatment of primary immune thrombocytopenia (ITP).
  • This randomized trial investigated rituximab efficacy in previously untreated adult ITP patients with a platelet count of 20 x 10(9)/L or less.
  • Patients who were refractory to dexamethasone alone received salvage therapy with dexamethasone plus rituximab.
  • Sustained response (ie, platelet count > or = 50 x 10(9)/L at month 6 after treatment initiation), evaluable in 101 patients, was greater in patients treated with dexamethasone plus rituximab (n = 49) than in those treated with dexamethasone alone (n = 52; 63% vs 36%, P = .004, 95% confidence interval [95% CI], 0.079-0.455).
  • Dexamethasone plus rituximab was an effective salvage therapy in 56% of patients refractory to dexamethasone.
  • Thus, combination therapy may represent an effective treatment option before splenectomy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dexamethasone / administration & dosage. Purpura, Thrombocytopenic, Idiopathic / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Platelet Count. Rituximab. Time Factors


35. Ling Y, Cao X, Yu Z, Ruan C: Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol; 2007 Oct;79(4):310-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome.
  • Immune thrombocytopenic purpura (ITP) is an autoimmune disorder, and high-dose dexamethasome (HD-DXM) has been used as a first-line therapy for patients with ITP.
  • In this study, we investigated the amounts of circulating myeloid DCs (mDCs), plasmacytoid DCs (pDCs), and CD4(+)Foxp3(+) Treg cells in 26 untreated adult patients with chronic ITP.
  • We also observed short-time changes of DCs and Treg cells after treatment with HD-DXM in these patients.
  • After 4-days treatment with HD-DXM, Treg cells and mDCs were increased (P < 0.0001 and P < 0.05), while pDCs decreased (P < 0.0001), and CD11c expression level in mDCs was downregulated (P < 0.0001).
  • These results suggest that Treg cells are deficient in ITP and the immunosuppressive therapy of glucocorticoids could cause the short-time changes of these cells.
  • [MeSH-major] Dendritic Cells / immunology. Dexamethasone / administration & dosage. Forkhead Transcription Factors. Glucocorticoids / administration & dosage. Purpura, Thrombocytopenic, Idiopathic / drug therapy. Purpura, Thrombocytopenic, Idiopathic / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. Antigens, CD11c / immunology. CD4 Lymphocyte Count. Chronic Disease. Down-Regulation / drug effects. Female. Humans. Immunosuppression. Male. Middle Aged. Myeloid Cells / immunology. Myeloid Cells / pathology. Plasma Cells / immunology. Plasma Cells / pathology. Platelet Count

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692100.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD11c; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


36. Usui N, Dobashi N, Asai O, Yano S, Kato A, Osawa H, Uno S, Katori M, Nagamine M, Yahagi Y, Yamaguchi Y, Saito T, Kasama K, Takei Y, Ogihara A, Yamazaki H, Kobayashi T, Tajima N, Ogawa M, Kuraishi Y: [The role of daunorubicin in induction therapy for adult acute myeloid leukemia]. Gan To Kagaku Ryoho; 2000 Jul;27(8):1152-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
  • The relationship between the total dose of daunorubicin (DNR) in induction therapy and the treatment outcome were evaluated based upon individualized doses of DNR during induction therapy for patients with acute myeloid leukemia(AML).
  • Ninety-two previously untreated adult AML patients admitted to our hospital were analyzed for the dose of DNR required for complete remission (CR), the CR rate, disease-free survival (DFS) and overall survival (OS).
  • The induction therapy consisted of DNR (40 mg/m2/d, i.v., from D 1 until the marrow was hypoplastic), Ara-C, prednisolone, and/or 6-thioguanine.
  • Sixty-three patients entered CR (76%), of whom 52 attained CR with the first course of induction therapy.
  • The median total dose of DNR in the induction therapy was 280 mg/m2 (120-480 mg/m2), which was not influenced by initial WBC count, or FAB type.
  • These results indicate that when the dose is linked to the observed tumor response, the optimal dose of DNR in the induction therapy is around 280 mg/m2 (40 mg/m2 x 7 times), which is higher than the conventional dose of 40-60 mg/m2 for 3 days.
  • The higher dose of DNR in the induction therapy for adult AML should be selected when the feasibility of a new drug is evaluated in a randomized trial.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Daunorubicin / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10945010.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


37. Silbergeld A, Lilos P, Laron Z: Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency. J Pediatr Endocrinol Metab; 2007 Dec;20(12):1325-8
MedlinePlus Health Information. consumer health - Foot Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency.
  • OBJECTIVE: To compare foot length deficits between patients with Laron syndrome (LS) (primary growth hormone [GH] insensitivity) and congenital isolated GH deficiency (IGHD) and their response to replacement therapy with insulin-like growth factor-I (IGF-I) and hGH, respectively.
  • Fifteen non-treated adult patients with LS were also included in the study.
  • METHODS: Measurements of foot length were recorded without treatment and monitored during 9 years of treatment in the children and in the untreated adult patients.
  • RESULTS: With almost similar basal values in growth deficit and pre-treatment growth velocities, the achievements towards norms after 9 years of treatment were greater in the patients with IGHD than in the patients with LS: foot length reached -1.4 +/- 0.8 vs. -3.3 +/- 1.0 SDS (mean +/- SD), and body height -2.2 +/- 1.0 vs. -3.9 +/- 0.5 SDS.
  • The difference between the two groups could be due to the initiation of replacement therapy in the patients with IGHD at a younger age.
  • Adult foot size of untreated patients with LS is small but less retarded than the height deficit.
  • [MeSH-major] Dwarfism, Pituitary / drug therapy. Foot / growth & development. Growth Hormone / therapeutic use. Insulin-Like Growth Factor I / therapeutic use. Laron Syndrome / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Body Height / drug effects. Child. Female. Hormone Replacement Therapy / methods. Humans. Male. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Growth Hormone Deficiency.
  • Genetic Alliance. consumer health - Laron syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341092.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


38. Thomas X, Le QH, Danaïla C, Lhéritier V, Ffrench M: Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors. Leuk Res; 2002 Oct;26(10):909-18
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors.
  • Bone marrow (BM) sections were examined in 128 untreated adult patients with newly diagnosed acute lymphoblastic leukemia (ALL), seen in our institution over a 19-year period.
  • All patients, but four, received standard ALL induction chemotherapy according to different successive protocols.
  • [MeSH-major] Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Biopsy. Cytodiagnosis. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12163052.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Dogan EA, Usta BE, Bilgen R, Senol Y, Aktekin B: Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav; 2008 Jul;13(1):156-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy.
  • OBJECTIVE: The aim of the study described here was to investigate the efficacy, tolerability, and side effects of oxcarbazepine (OXC) monotherapy in newly diagnosed, previously untreated adult and elderly patients with partial epilepsy.
  • Overall, 92 patients (62.6%) were seizure free for at least 12 months and 55 of them (37.4%) were unresponsive despite treatment with the maximum tolerable dose of OXC.
  • OXC proved to be a tolerable drug for the elderly; only one patient experienced symptomatic hyponatremia with mild symptoms and responded well to fluid restriction, which did not lead to discontinuation of OXC.
  • CONCLUSION: Although the limitations of our study include its open-label design, the results suggest that OXC monotherapy may be regarded as an effective first-line monotherapy option for adult and elderly patients with partial epilepsy, but has low efficacy in patients with cerebral tumors.
  • [MeSH-major] Anticonvulsants / therapeutic use. Carbamazepine / analogs & derivatives. Epilepsy / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Drug Evaluation. Female. Humans. Male. Middle Aged. Prospective Studies. Retrospective Studies

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. OXCARBAZEPINE .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331816.001).
  • [ISSN] 1525-5069
  • [Journal-full-title] Epilepsy & behavior : E&B
  • [ISO-abbreviation] Epilepsy Behav
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 33CM23913M / Carbamazepine; VZI5B1W380 / oxcarbazepine
  •  go-up   go-down


40. Mazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, De Marinis L, Giustina A: Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res; 2006 Apr;21(4):520-8
MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.
  • This cross-sectional study shows that a high number of untreated adult patients with GHD develop radiological vertebral deformities.
  • Patients undergoing GH replacement treatment showed a significantly lower prevalence of vertebral deformities versus treated patients in the presence of similar BMD, as assessed by DXA.
  • INTRODUCTION: In this cross-sectional study, we investigated whether the prevalence and degree of spinal deformities in adults with growth hormone deficiency (GHD) were related to the age of patients, degree of bone turnover, BMD, and recombinant human GH (rhGH) replacement therapy.
  • MATERIALS AND METHODS: One hundred seven adult hypopituitary patients (67 males and 40 females; mean age, 47 years; range: 16-81 years) with severe GHD and 130 control subjects (39 males, 91 females; mean age: 58.9 years; range: 26-82 years) were evaluated for BMD (DXA) and vertebral deformities (quantitative morphometric analysis).
  • At study entry, 65 patients were on replacement therapy with rhGH, whereas 42 patients had never undergone rhGH.
  • The fracture prevalence, as well as the fracture number, was significantly higher in untreated versus treated patients (78.6% versus 53.8%; chi2: 6.7; p = 0.009), although the two groups of patients did not show any significant difference in median T score.
  • In untreated GHD patients, the prevalence of vertebral deformities was correlated with T score (p = 0.002) and duration of disease (p = 0.003).
  • CONCLUSIONS: This cross-sectional study reports high prevalence of vertebral radiological deformities in adult patients with untreated GHD.
  • The replacement treatment of GHD leads to a significant decrease in fracture rate.
  • [MeSH-major] Hormone Replacement Therapy. Human Growth Hormone / deficiency. Human Growth Hormone / pharmacology. Spine / abnormalities. Spine / drug effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Density / physiology. Cross-Sectional Studies. Female. Fractures, Bone / epidemiology. Humans. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Spinal Deformities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598371.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


41. Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA: Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol; 2000 Feb;20(2):500-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Premature coronary heart disease occurs in approximately 30% of heterozygous untreated adult patients.
  • The families who consumed this margarine for 12 weeks included 24 children, aged 3 to 13 years, with the North Karelia variant of FH (FH-NK), 4 FH-NK parents, and 16 healthy family members, and a separate group of 12 FH-NK adults who consumed the margarine for 6 weeks and who were on simvastatin therapy (20 or 40 mg/d).
  • As assayed in a genetically defined population of FH patients, a dietary regimen with stanol ester margarine proved to be a safe and effective hypolipidemic treatment for children and adults.
  • In FH-NK adults on simvastatin therapy, serum LDL cholesterol levels could be reduced even further by including a stanol ester margarine in the regimen.
  • [MeSH-major] Androstanols / pharmacology. Anticholesteremic Agents / therapeutic use. Cholesterol / blood. Esters / therapeutic use. Hyperlipoproteinemia Type II / diet therapy. Hyperlipoproteinemia Type II / drug therapy. Margarine. Mutation / physiology. Simvastatin / therapeutic use. Sterols / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cholesterol, LDL / blood. Drug Therapy, Combination. Female. Finland. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Familial Hypercholesterolemia.
  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10669649.001).
  • [ISSN] 1079-5642
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Androstanols; 0 / Anticholesteremic Agents; 0 / Cholesterol, LDL; 0 / Esters; 0 / Sterols; 8029-82-1 / Margarine; 97C5T2UQ7J / Cholesterol; AGG2FN16EV / Simvastatin
  •  go-up   go-down


42. Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS: CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leuk Lymphoma; 2003 Jun;44(6):967-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
  • The role of high dose therapy, including autologous stem cell transplantation (ASCT) in indolent non-Hodgkin's lymphomas remains controversial.
  • We evaluated a dose intense regimen of CHOP induction followed by high dose cyclophosphamide consolidation (CHOP-HC) versus CHOP alone in a prospective comparison to assess intensified therapy without ASCT.
  • Twenty-five patients with previously untreated advanced stage indolent NHL were enrolled: follicular lymphoma, grade 1 (11 patients) and grade 2 (8 patients); small lymphocytic lymphoma (5 patients); and lymphoplasmacytic lymphoma (1 patient).
  • There were no treatment-related deaths.
  • No myelodysplasia or acute leukemia has been seen to date.
  • With no obvious improvement in CR and with greater hematologic toxicity than CHOP, CHOP-HC is not recommended for treatment of indolent non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Rate. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down


43. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood; 2008 Feb 1;111(3):1060-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia.
  • Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible.
  • Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia.
  • Common drug-related adverse experiences were diarrhea, nausea, fatigue, and anorexia and were mild/moderate in severity.
  • Grade 3/4 drug-related adverse experiences included fatigue (27%), thrombocytopenia (12%), and diarrhea (10%).
  • There were no drug-related deaths; 7 patients had hematologic improvement response, including 2 complete responses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD).
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Histone Deacetylase Inhibitors. Hydroxamic Acids / therapeutic use. Leukemia / drug therapy. Leukemia / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Acetylation. Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials, Phase I as Topic. Dose-Response Relationship, Drug. Drug Tolerance. Drug-Related Side Effects and Adverse Reactions. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Histones / metabolism. Humans. Male. Middle Aged. Neoplasm Staging






Advertisement